Bank of America Global Healthcare Conference 2026
Logotype for CG Oncology Inc

CG Oncology (CGON) Bank of America Global Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for CG Oncology Inc

Bank of America Global Healthcare Conference 2026 summary

12 May, 2026

Strategic initiatives and portfolio transformation

  • Completed the carve-out and IPO of Janus, a senior housing REIT, raising $900 million and positioning it for rapid growth with low leverage and significant cash for M&A.

  • Healthpeak now manages two REITs, retaining 80% ownership of Janus, and is seeing improved valuation multiples and embedded value in its stock price.

  • Outpatient medical buildings remain the largest business segment, with a focus on high-quality, hospital-affiliated assets and ongoing portfolio optimization through selective sales and reinvestment.

  • Lab/life science real estate is a core growth area, with recent acquisitions in South San Francisco and significant undeveloped land in Cambridge and San Francisco for future expansion.

  • Senior housing, through Janus, benefits from a unique 100% RIDEA/SHOP model, enabling higher growth and direct participation in operational performance.

Market trends and operational performance

  • Outpatient medical buildings have demonstrated 22 years of NOI growth and high rent collection, with strong demand driven by the shift of care from hospitals to outpatient settings.

  • Lab business faced occupancy declines due to overbuilding but is showing signs of recovery, with recent positive net absorption and long-term upside from strategic acquisitions.

  • Senior housing experienced a post-COVID rebound, with supply constraints and rising demand creating a favorable environment for NOI and revenue growth.

  • Cap rates for outpatient medical buildings remain attractive, especially for hospital-affiliated and ASC-anchored properties, with high liquidity and institutional interest.

  • Healthpeak’s dividend yield stands at 7%, with a 70% payout ratio and underlying cash flow growth of about 10%.

Growth outlook and capital allocation

  • Janus is positioned to double or triple in size over the next two years, leveraging IPO proceeds and debt capacity for acquisitions and development.

  • Healthpeak may eventually spin off or monetize its Janus stake, with both businesses potentially operating independently as they grow.

  • Outpatient medical and lab segments are focused on growth in major markets, with new developments pre-leased to investment-grade health systems and ongoing portfolio pruning.

  • Lab real estate strategy includes acquiring underperforming assets at attractive prices and capitalizing on long-term demand in core markets.

  • The company is well-positioned to benefit from demographic trends, healthcare delivery shifts, and real estate market dynamics.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more